TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3582167
Drug: DIS and
Normalized name: di-isopropylammonium
Approvals — FDA: no, EMA: no, PMDA: no
Description: DIS and SADS-L
Study: 29374672
Drug: rfMDA (presumptive
Approvals — FDA: no, EMA: no, PMDA: no
Description: rfMDA (presumptive treatment with artemether-lumefantrine)
Study: 29374672
Drug: RACD (rapid
Approvals — FDA: no, EMA: no, PMDA: no
Description: RACD (rapid diagnostic testing and treatment using artemether-lumefantrine)
Study: 22781525
Drug: Ultrasound guidance
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guidance for ilioinguinal or iliohypogastric nerve block with 0.8% lidocaine and 0.25% levobupivacaine at 0.2 ml/kg (Group U)
Study: 22781525
Drug: Traditional method
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional method of anatomical localization with 0.3 ml/kg of the same local anesthetic (Group T)
Study: 18669967
Drug: Eprex (pre‐operative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprex (pre‐operative injections of epoetin)
Study: 15753747
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline dextran (HSD) 250 mL
Study: 15753747
Drug: Conventional fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fluid regimen with hydroxyethyl starch in normal saline solution (H-NS) 250 mL
Study: 12704010
Drug: Internet intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Internet intervention (Web site plus 12 weekly e‐mail tip sheets)
Study: 9814858
Drug: Therapy-naive patients
Normalized name: lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Therapy-naive patients
Study: 7735716
Drug: Dietary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary and pharmacologic agents
Study: 62998
Drug: Dapsone 5
Normalized name: dapsone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone 5 mg daily
Study: 62998
Drug: Dapsone 50
Normalized name: dapsone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone 50 mg daily
Study: 28816833
Drug: Erythromycin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (25 mg/kg before and after surgery)
Study: 19780000
Drug: Thiocolchicoside ointment
Normalized name: thiocolchicoside
DrugBank: Thiocolchicoside (DB11582)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiocolchicoside ointment applied onto the trigger points
Study: 19780000
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg thiocolchicoside intramuscular injection to the trigger points
Study: 19780000
Drug: Both thiocolchicoside
Normalized name: thiocolchicoside
DrugBank: Thiocolchicoside (DB11582)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both thiocolchicoside ointment and intramuscular injection
Study: 11735185
Drug: Aspirin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (150 mg) and below-knee compression stockings (Class 1 profile)
Study: 11735185
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no aspirin or stockings)
Study: 8315162
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (standard nutrition care for subjects with IDDM)
Study: 8315162
Drug: SHAPEDOWN program
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHAPEDOWN program and Standard treatment
Study: 3830242
Drug: Felodipine 10
Normalized name: felodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 10 mg b.d.
Study: 3830242
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg b.d.
Study: 3830242
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of felodipine and metoprolol
Study: 22057073
Drug: Clonazepam (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (5 mg to 10 mg)
Study: 22057073
Drug: Zolpidem (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (1 mg)
Study: 11915778
Drug: High-carbohydrate diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-carbohydrate diet (CD; 9-10 g carbohydrate/kg lean body mass)
Study: 11915778
Drug: Habitual diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Habitual diet (HD; 6-7 g carbohydrate/kg lean body mass)
Study: 8056728
Drug: Clozapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (mean sixth week daily dose 370 mg)
Study: 31809216
Drug: AR19 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR19 5 mg
Study: 31809216
Drug: AR19 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR19 20 mg (intact capsule with meal)
Study: 31809216
Drug: AR19 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR19 20 mg (fasted)
Study: 31809216
Drug: AR19 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR19 30 mg
Study: 28691360
Drug: 10% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% lidocaine spray applied to the ectocervix
Study: 16562643
Drug: Ciprofibrat 100
Normalized name: ciprofibrate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofibrat 100 mg
Study: 4059666
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP) 100 micrograms qds
Study: 22166561
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (peginterferon alfa-2a 180 µg/week + ribavirin 1,000/1,200 mg/day + amantadine 200 mg/day)
Study: 20969664
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid filler injections
Study: 17377646
Drug: Pharmaceutical industry
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical industry sponsorship
Study: 9041968
Drug: Intrapleural streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural streptokinase (SK), 250,000 U in saline solution, mean duration 5.3 days
Study: 3296288
Drug: Nifedipine (30-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (30-80 mg)
Study: 3296288
Drug: Verapamil (120-360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (120-360 mg)
Study: 3296288
Drug: Phendilin (150-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phendilin (150-300 mg)
Study: 23455663
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (clinical drug treatment with Methotrexate, Leflunomide and/or Prednisone)
Study: 20520603
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of ephedra dry extract
Study: 20520603
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of ephedra dry extract
Study: 18799032
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (RT+BP, RT+TP, RT+FP)
Study: 16651305
Drug: Dichloroacetate (DCA)
Normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichloroacetate (DCA) at a dose of 12.5 mg/kg every 12 hours for 6 months
Study: 12792354
Drug: Prednisone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (40 mg once daily for 14 days)
Study: 10981801
Drug: Nicardipine in
Normalized name: nicardipine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine in an aqueous gel vehicle
Study: 1582603
Drug: Glucose based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose based ORS plus food from the beginning of treatment (group B)
Study: 1582603
Drug: Rice based
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice based ORS plus food from start of therapy (group D)
Study: 6375979
Drug: Fluorometholone acetate
Normalized name: Fluorometholone Acetate
DrugBank: Fluorometholone (DB00324)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluorometholone acetate ophthalmic suspension
Study: 6375979
Drug: Dexamethasone sodium
Normalized name: dexamethasone sodium phosphate
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone sodium phosphate ophthalmic solution
Study: 30059750
Drug: Adaptive servo-ventilation
Normalized name: Servo Stat Bac
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adaptive servo-ventilation (ASV) with optimal medical therapy (OMT)
Study: 25441855
Drug: Postoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative treatment with elastic bandage
Study: 18583576
Drug: Montelukast 4
Normalized name: montelukast 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 4 mg/day
Study: 18583576
Drug: Montelukast 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 8 mg/day
Study: 12047489
Drug: Monosodium (L)-glutamate
Normalized name: Monosodium Glutamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monosodium (L)-glutamate (10 g)
Study: 9952072
Drug: Panamesine (PAN)
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Panamesine (PAN) 90 mg/day
Study: 9952072
Drug: Panamesine (PAN)
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Panamesine (PAN) 30 mg
Study: 2160354
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate (750 mg)
Study: 6680021
Drug: Cyclical levamisole
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclical levamisole treatment (150 mg daily for 3 days repeated after a gap of 2 weeks) in addition to standard DDS treatment
Study: 6680021
Drug: Standard DDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard DDS treatment and placebo
Study: 6680021
Drug: Cyclical levamisole
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclical levamisole treatment
Study: 31662536
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of platinum agents (PTs)
Study: 31662536
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of platinum agents (PTs) or switching to non-platinum agents
Study: 30239425
Drug: Dispersible FDC
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispersible FDC tablet of abacavir 150 mg/dolutegravir 10 mg/lamivudine 75 mg administered in high- or zero-mineral content water, either immediately or after a 30-minute delay.
Study: 30239425
Drug: Nondispersible dolutegravir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nondispersible dolutegravir 10 mg tablets plus nondispersible abacavir 600 mg/lamivudine 300 mg tablet administered with zero-mineral content water.
Study: 27426855
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin 75 mg and heparin 5000 IU subcutaneous every 12 h
Study: 27426855
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin and heparin
Study: 24299019
Drug: Atorvastatin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin plus omega-3 fatty acid ethyl esters (4 g/day)
Study: 17823519
Drug: Daivobet/Dovobet/Taclonex (calcipotriol/betamethasone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daivobet/Dovobet/Taclonex (calcipotriol/betamethasone) once daily
Study: 17823519
Drug: Non-fix calcipotriol/betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-fix calcipotriol/betamethasone combination (morning/evening)
Study: 1376197
Drug: Operative and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative and nonoperative treatment options based on prostate size
Study: 1376197
Drug: Interactive video
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive video disc for explaining treatment options
Study: 3975120
Drug: High-dose phototherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose phototherapy (12 microW/cm2/nm)
Study: 3975120
Drug: Low-dose phototherapy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose phototherapy (6 microW/cm2/nm)
Study: 23279372
Drug: sCD30 concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: sCD30 concentration ≥40.3 U/ml on day 14
Study: 23279372
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of steroids
Study: 21995804
Drug: Paramedic cooling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paramedic cooling during CPR using rapid infusion of ice-cold normal saline (4 °C, 20-40 mL/kg to a maximum of 2 litres)
Study: 21995804
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment during CPR
Study: 18812677
Drug: Low-dose carperitide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose carperitide (0.01-0.05 microg x kg(‐1 ) x min(‐1)) for 72 hours
Study: 16860048
Drug: Advance provision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advance provision of emergency contraception (2 x 0.75 mg levonorgestrel pills - Plan B)
Study: 10988110
Drug: Pamidronate (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (30 mg intravenously every 3 months) with vitamin D (800 IU/d) and calcium (1 g/d)
Study: 10988110
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (800 IU/d) and calcium (1 g/d) alone (Control)
Study: 1291309
Drug: Clindamycin 150
Normalized name: clindamycin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 150 mg every 6 h for seven days
Study: 1291309
Drug: Phenoxymethylpenicillin 1
Normalized name: phenoxymethylpenicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenoxymethylpenicillin 1 g every 12 h for seven days
Study: 28055000
Drug: Pharmacological approaches
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological approaches (e.g., step‐up/down; self‐management; simplified regimen) and non‐pharmacological approaches (e.g., trigger management, education, social support; inhaler technique).
Study: 26948284
Drug: 49-mg p-synephrine
Normalized name: synephrine
DrugBank: Synephrine (DB09203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 49-mg p-synephrine
Study: 9431375
Drug: Intravenous ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir followed by oral acyclovir (10 mg/[kg.d] for 2 weeks, then 800 mg/m2 four times daily for 50 weeks)
Study: 9431375
Drug: Intravenous ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir alone (10 mg/[kg.d] for 2 weeks)
Study: 9431375
Drug: Intravenous ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir followed by oral acyclovir
Study: 3014851
Drug: Suloctidil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suloctidil (200 mg 3 times daily)
Study: 14712432
Drug: Daily hemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily hemodialysis (6 times/week)
Study: 2167820
Drug: Aluminium citrate
Normalized name: Aluminium
DrugBank: Aluminium phosphate (DB14517)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aluminium citrate (Al‐cit) treatment group, injected with 120 mg Al/year for five years
Study: 7028636
Drug: Trimethoprim/sulphadiazine (4/16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim/sulphadiazine (4/16 mg/kgBW/day in two doses) for 3 days
Study: 7028636
Drug: Trimethoprim/sulphadiazine (4/16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim/sulphadiazine (4/16 mg/kgBW/day in two doses) for 10 days
Study: 28545589
Drug: Positive control
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive control (5 g fructooligosaccharides mixed in lactose-free milk)
Study: 28545589
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (including low FODMAP ONS and positive control)
Study: 19640734
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic agent (prilocaine 2%) plus 500 microg nitroglycerin (group A)
Study: 19640734
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic agent (prilocaine 2%) (group B)
Study: 11094579
Drug: i.v. ondansetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ondansetron 4 mg (control)
Study: 11094579
Drug: i.v. ondansetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ondansetron 4 mg and cyclizine 50 mg (combination)
Study: 3550214
Drug: Prazosin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (2 mg 6 hr‐1)
Study: 3550214
Drug: Furosemide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (40 mg day‐1) with prazosin
Study: 3550214
Drug: Furosemide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (40 mg day‐1) with prazosin and captopril (25 mg 6 hr‐1)
Study: 3550214
Drug: Furosemide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (40 mg day‐1) alone
Study: 28961803
Drug: PF‐00547659 22.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐00547659 22.5 mg
Study: 28961803
Drug: PF‐00547659 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐00547659 75 mg
Study: 28961803
Drug: PF‐00547659 225
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐00547659 225 mg
Study: 26778925
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein diet (>3 g/kg/day)
Study: 26778925
Drug: Normal (habitual)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal (habitual) diet (2.6 ± 0.8 g/kg/day)
Study: 25246821
Drug: Gadoxetic acid
Normalized name: Gadoxetic acid
DrugBank: Gadoxetic acid (DB08884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadoxetic acid injection at 0.5 mL/s (n = 50)
Study: 25246821
Drug: Gadoxetic acid
Normalized name: Gadoxetic acid
DrugBank: Gadoxetic acid (DB08884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadoxetic acid injection at 1 mL/s (n = 51)
Study: 23810267
Drug: Pharmacist intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist intervention addressing individual needs related to asthma control, inhaler technique, and medication adherence
Study: 20971961
Drug: Nefopam 20
Normalized name: nefopam 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam 20 mg IV over 30 minutes
Study: 20971961
Drug: Nefopam 20
Normalized name: nefopam 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam 20 mg IV over 30 minutes (healthy volunteers)
Study: 18311576
Drug: Annual physical
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual physical examination, neck ultrasonography, and serum thyroid-stimulating hormone (TSH) measurement for patients undergoing thyroid lobectomy.
Study: 15765200
Drug: AQUANOVA solubilisate
Normalized name: mercurius solubilis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: AQUANOVA solubilisate (100 IU alpha-tocopheryl acetate and 400 mg crystalline vitamin C) in the form of vitaminized gummi bears
Study: 15765200
Drug: Reference products
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference products (conventional preparations)
Study: 1578626
Drug: Scopolamine butylbromide
Normalized name: Scopolamine butylbromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine butylbromide (0.2 mg.kg-1)
Study: 1578626
Drug: Scopolamine butylbromide
Normalized name: Scopolamine butylbromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine butylbromide (0.4 mg.kg-1)
Study: 4092801
Drug: 2.5% indomethacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% indomethacin solution applied 1 hour before UVB irradiation
Study: 29128649
Drug: In-person Present‐Centered
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-person Present‐Centered Therapy (PCT)
Study: 25005045
Drug: Ringerfundin® solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringerfundin® solution
Study: 25005045
Drug: Glucose/potassium‐based balanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose/potassium‐based balanced crystalloid solution
Study: 19128589
Drug: Amikacin therapy
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin therapy
Study: 12946545
Drug: Ketotifen ophthalmic
Normalized name: ketotifen ophthalmic
DrugBank: Ketotifen (DB00920)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketotifen ophthalmic solution (0.025%)
Study: 12946545
Drug: Desloratadine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine (5 mg tablets)
Study: 12946545
Drug: Ketotifen ophthalmic
Normalized name: ketotifen ophthalmic
DrugBank: Ketotifen (DB00920)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketotifen ophthalmic solution
Study: 12946545
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (ketotifen and desloratadine)
Study: 10644288
Drug: Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10 mg once in the evening)
Study: 10644288
Drug: Salmeterol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (50 microg [2 puffs] twice daily)
Study: 1362432
Drug: Somatostatin (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (continuous infusion of 250 micrograms/h for 5 days plus daily bolus administration of 250 micrograms)
Study: 30326906
Drug: Self-management exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management exercise program (5 sessions of 1.5 hours each) + information booklet + 18 sessions of spa therapy treatment (1 hour each)
Study: 30326906
Drug: Information booklet
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information booklet + 18 sessions of spa therapy treatment (1 hour each)
Study: 30326906
Drug: Information booklet
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information booklet + spa therapy